MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.28 -1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.69

Max

44.29

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+23.53% upside

Turustatistika
By TradingEconomics
Turukapital	196M 3.4B
Eelmine avamishind	45.48
Eelmine sulgemishind	44.28

Uudiste sentiment

By Acuity

50%

146 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4. jaan 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

4. jaan 2026, 23:40 UTC

Market Talk

Uudisväärsed sündmused

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4. jaan 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 23:17 UTC

Uudisväärsed sündmused

Spot Gold Rises 0.8% to $4,365.24/oz

4. jaan 2026, 23:16 UTC

Uudisväärsed sündmused

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4. jaan 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4. jaan 2026, 23:13 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4. jaan 2026, 23:12 UTC

Market Talk

Uudisväärsed sündmused

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4. jaan 2026, 21:00 UTC

Tulu

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3. jaan 2026, 18:59 UTC

Uudisväärsed sündmused

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 17:42 UTC

Uudisväärsed sündmused

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3. jaan 2026, 17:40 UTC

Uudisväärsed sündmused

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 16:10 UTC

Uudisväärsed sündmused

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3. jaan 2026, 15:53 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 15:03 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 14:10 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 12:16 UTC

Uudisväärsed sündmused

U.S. Captures Maduro, Trump Says -- Barrons.com

3. jaan 2026, 09:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

3. jaan 2026, 09:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

3. jaan 2026, 00:43 UTC

Omandamised, ülevõtmised, äriostud

Research Reports -- Barrons.com

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

23.53% tõus

12 kuu keskmine prognoos

Keskmine 54.96 USD 23.53%

Kõrge 65 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

146 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.